4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime and Pain

4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime has been researched along with Pain* in 2 studies

Reviews

1 review(s) available for 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime and Pain

ArticleYear
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
    Journal of medicinal chemistry, 2010, Jul-22, Volume: 53, Issue:14

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Asthma; Humans; Ion Channel Gating; Neurons; Pain; Peripheral Nervous System Diseases; Pulmonary Disease, Chronic Obstructive; Transient Receptor Potential Channels

2010

Other Studies

1 other study(ies) available for 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime and Pain

ArticleYear
7-Substituted-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives as antagonists of the transient receptor potential ankyrin 1 (TRPA1) channel: a promising approach for treating pain and inflammation.
    Bioorganic & medicinal chemistry, 2012, Mar-01, Volume: 20, Issue:5

    The transient receptor potential ankyrin 1 (TRPA1) channel is activated by a series of by-products of oxidative/nitrative stress, produced under inflammatory conditions or in the case of tissue damage, thus generating inflammatory and neuropathic pain and neurogenic inflammatory responses. These findings have identified TRPA1 as an emerging opportunity for the design and synthesis of selective inhibitors as potential analgesic and antiinflammatory agents. Herein we present the synthesis and functional evaluation of a new series of 7-substituted-1,3-dimethyl-1,5-dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione derivatives designed as TRPA1 antagonists. A small library of compounds has been built by the introduction of differently substituted N(7)-phenylacetamide or N(7)-[4-(substituted-phenyl)-thiazol-2-yl]-acetamide chains. All the synthesized compounds were assayed to evaluate their ability to block acrolein-mediated activation of native human and rat TRPA1 channels employing a fluorometric calcium imaging assay. Our study led us to the identification of compound 3h which showed considerably improved potency (IC(50)=400nM) against human TRPA1 with regard to some of the most representative antagonists previously reported and integrated in our screening program as reference compounds. In addition, 3h proved to maintain its efficacy toward rTRPA1, which designates it as a possible candidate for future evaluation of in vivo efficacy in rodent animal model of inflammatory and neuropathic pain.

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channels; Humans; Inflammation; Male; Nerve Tissue Proteins; Pain; Pyrimidines; Rats; Rats, Sprague-Dawley; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPC Cation Channels

2012